Managing hypertension in cardiology practice according to risk profile

International Journal of Clinical Practice

Volumn 62, Issue 9, 2008, Pages 1403-1412

  Volpe, M ^a,b,c   Tocci, G ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE CONTROL; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MICROALBUMINURIA; MONOTHERAPY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; SODIUM RESTRICTION; TREATMENT OUTCOME; WEIGHT REDUCTION;

CARDIOLOGY; CLINICAL COMPETENCE; COMBINED MODALITY THERAPY; HUMANS; HYPERTENSION; PROFESSIONAL PRACTICE; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 49349099859     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01821.x     Document Type: Review

References (84)

1. Lawes CM, Vander HS, Law MR et al. Blood pressure and the global burden of disease 2000. Part 1: estimates of blood pressure levels. J Hypertens 2006 24: 413 22.
2. Lawes CM, Vander HS, Law MR et al. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens 2006 24: 423 30.
3. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 365: 217 23.
4. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996 275: 1571 6.
5. Ezzati M, Lopez AD, Rodgers A et al. Selected major risk factors and global and regional burden of disease. Lancet 2002 360: 1347 60.
6. Franco OH, Peeters A, Bonneux L et al. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension 2005 46: 280 6.
7. Wolf-Maier K, Copper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003 289: 2363 9.
8. Boersma E, Keil U, De Bacquer D et al. for the EUROASPIRE I and II Study Groups. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003 21: 1831 40.
9. Lim SS, Gaziano TA, Gakidou E et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 2007 370: 2054 62.
10. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002 20: 1461 4.
11. Ruilope LM, Volpe M. The case for blood pressure control in risk groups. Int J Clin Pract 2004 58: 844 9.
12. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000 13: 3S 10S.
13. Mancia G, Ambrosioni E, Rosei EA et al. for the ForLife study group. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005 23: 1575 81.
14. Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract 2008 62: 97 108.
15. Mancia G, De Backer G, Dominiczak A et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 25: 1105 87.
16. Alderman MH, Furberg CD, Kostis JB et al. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens 2002 15: 917 23.
17. Volpe M, Alderman MH, Furberg CD et al. Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens 2004 17: 1068 74.
18. Bramlage P, Thoenes M, Kirch W et al. Clinical practice and recent recommendations in hypertension management - reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin 2007 23: 783 91.
19. Llisterri Caro JL, Rodriguez Roca GC, Alonso Moreno FJ et al. Blood pressure control in Spanish hypertensive patients in Primary Health Care Centres. PRESCAP 2002 Study. Med Clin (Barc) 2004 122: 165 71.
20. Amar J, Vaur L, Perret M et al. Arterial hypertension management in general practice in France according to global risk factors. Arch Mal Coeur Vaiss 2001 94: 843 5.
21. Oriol-Zerbe C, Abholz HH. Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators. Eur J Gen Pract 2007 13: 27 34.
22. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002 19: 596 604.
23. Volpe M, Tocci G, Trimarco B et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007 25: 1491 8.
24. European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. J Hypertension 2003 21: 1011 53.
25. Backlund L, Bring J, Strender LE. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients? Prim Health Care Res Devel 2004 5: 145 52.
26. Volpe M, Dedhiya SD. Physicians, patients, and public knowledge and perception regarding hypertension and stroke: a review of survey studies. Curr Med Res Opin 2006 22: 1319 30.
27. Volpe M, Tocci G, Pagannone E. Less mega-trials and more clinically oriented studies in hypertension research? The case of blocking Renin-Angiotensin-Aldosterone System J Am Soc Nephrol 2006 17: S36 43.
28. Volpe M, Tocci G. Antihypertensive therapy and cerebrovascular protection. Curr Opin Nephrol Hypertens 2006 15: 498 504.
29. Volpe M. Evidence-based indications in hypertensive patients: helping doctors in the initial choice. High Blood Press Cardiovasc Prev 2004 11: 1 7.
30. Joint National Committee on Prevention. Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC VI report. Arch Intern Med 1997 157: 2413 45.
31. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the second report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel II). JAMA 1993 269: 3015 23.
32. World Health Organization (WHO)/International Society of Hypertension (ISH) guidelines for the management of hypertension. J Hypertens 1999 17: 151 83.
33. Lewington S, Clarke R, Qizilbash N et al. for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 360: 1903 13.
34. Tocci G, Sciarretta S, Volpe M. Heart failure development in recent hypertension trials. J Hypertens 2008 26: 1477 86.
35. Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med 1986 15: 254 73.
36. Martiniuk AL, Lee CM, Lawes CM et al. for the Asia-Pacific Cohort Studies Collaboration. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007 25: 73 9.
37. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 364: 937 52.
38. Wolf PA, D'Agostino RB, Belanger AJ et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991 22: 312 8.
39. Tunstall-Pedoe H. The Dundee coronary risk-disk for management of change in risk factors. BMJ 1991 303: 744 7.
40. Voss R, Cullen P, Schulte H et al. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 2002 31: 1253 62.
41. Haq IU, Ramsay LE, Yeo WW et al. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999 81: 40 6.
42. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000 21: 365 70.
43. Thomsen TF, McGee D, Davidsen M et al. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002 31: 817 22.
44. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 24: 987 1003.
45. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 362: 1527 45.
46. Turnbull F, Neal B, Algert C et al. Effects of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005 165: 1410 9.
47. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007 25: 951 8.
48. Pignone M, Mulrow CD. Evidence based management of hypertension: using cardiovascular risk profiles to individualise hypertensive treatment. BMJ 2001 322: 1164 6.
49. Hypertension: uncontrolled and conquering the world. Lancet 2007 370: 539.
50. Volpe M, Erhardt LR, Williams B. Managing cardiovascular risk: the need for change. J Hum Hypertens 2008 22: 154 7.
51. Tocci G, Sciarretta S, Facciolo C, Volpe M. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Rev Cardiovasc Ther 2007 5: 767 76.
52. Ruilope LM, Rosei EA, Bakris GL et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press 2005 14: 196 209.
53. ALLHAT Officiers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 288: 2981 97.
54. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 366: 895 906.
55. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003 21: 875 86.
56. Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000 356: 359 65.
57. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004 363: 2022 31.
58. Black HR, Elliott WJ, Grandits G et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003 289: 2073 82.
59. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003 290: 2805 16.
60. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359: 995 1003.
61. Devereux RB, Dahlof B. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Curr Med Res Opin 2007 23: 443 57.
62. Devereux R, de Faire U, Fyhrquist F et al. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin 2007 23: 259 70.
63. Okin PM, Devereux RB, Jern S et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003 108: 684 90.
64. Ibsen H, Wachtell K, Olsen MH et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004 22: 1805 11.
65. Hoieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004 65: 1041 9.
66. Gerdts E, Oikarinen L, Palmieri V et al. for the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study. Hypertension 2002 39: 739 43.
67. Wachtell K, Hornestram B, Lehto M et al. Cardiovascular mortality and morbidity in hypertensive patients with atrial fibrillation: the LIFE study. J Am Coll Cardiol 2005 45: 705 11.
68. Wachtell K, Lehto M, Hornestram B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for Endpoint reduction (LIFE) study. J Am Coll Cardiol 2005 45: 712 9.
69. Olsen MH, Wachtell K, Tuxen C et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005 23: 1083 90.
70. Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002 20: 1879 86.
71. Olsen ME, Wachtell K, Beevers G et al. Losartan has positive effects on lipid metabolism compared to atenolol in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study [abstract]. J Am Coll Cardiol 2005 45 (Suppl A): 423A.
72. Olsen MH, Wachtell K, Neland K et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005 14: 177 83.
73. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 106: 672 8.
74. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 345: 870 8.
75. Lewis E, Hunsicker L, Clarke W et al. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 345: 851 60.
76. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359: 1004 10.
77. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 345: 861 9.
78. Mulrow CD, Pignone M. What are the elements of good treatment for hypertension? BMJ 2001 322: 1107 9.
79. Israili ZH, Hernandez-Hernandez R, Valasco M. The future of antihypertensive treatment. Am J Ther 2007 14: 121 34.
80. Bangalore S et al. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007 50: 563 72.
81. Williams B, Poulter NR, Brown MJ et al. for the British Hypertension Society (BHS) Guidelines. Guidelines of management of hypertension: report of the fourth working party on British Hypertension Society - BHS IV. J Hum Hypertens 2004 18: 139 85.
82. The Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Preliminary results presented at ACC '08 Meeting, Chicago, IL, 31 March 2008.
83. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 358: 580 91.
84. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007 120: 713 9.